Rocha Ricardo, Martin-Berger Cynthia L, Yang Pochang, Scherrer Rachel, Delyani John, McMahon Ellen
Pharmacia Corporation, Cardiovascular and Metabolic Diseases, Skokie, Illinois 60077 and St. Louis, Missouri 63167, USA.
Endocrinology. 2002 Dec;143(12):4828-36. doi: 10.1210/en.2002-220120.
We studied the role of aldosterone (aldo) in myocardial injury in a model of angiotensin (Ang) II-hypertension. Wistar rats were given 1% NaCl (salt) to drink and randomized into one of the following groups (n = 10; treatment, 21 d): 1) vehicle control (VEH); 2) Ang II infusion (25 ng/min, sc); 3) Ang II infusion plus the selective aldo blocker, eplerenone (epl, 100 mg/kg.d, orally); 4) Ang II infusion in adrenalectomized (ADX) rats; and 5) Ang II infusion in ADX rats with aldo treatment (20 micro g/kg.d, sc). ADX rats received also dexamethasone (12 micro g/kg.d, sc). Systolic blood pressure increased with time in all treatment groups except the VEH group (VEH, 136 +/- 6; Ang II/NaCl, 203 +/- 12; Ang II/NaCl/epl, 196 +/- 10; Ang II/NaCl/ADX, 181 +/- 7; Ang II/NaCl/ADX/aldo, 236 +/- 8 mm Hg). Despite similar levels of hypertension, epl and ADX attenuated the increase in heart weight/body weight induced by Ang II. Histological examination of the hearts evidenced myocardial and vascular injury in the Ang II/salt (7 of 10 hearts with damage, P < 0.05 vs. VEH) and Ang II/salt/ADX/aldo groups (10 of 10 hearts with damage, P < 0.05). Injury included arterial fibrinoid necrosis, perivascular inflammation (primarily macrophages), and focal infarctions. Vascular lesions were associated with expression of the inflammatory mediators cyclooxygenase 2 (COX-2) and osteopontin in the media of coronary arteries. Myocardial injury, COX-2, and osteopontin expression were markedly attenuated by epl treatment (1 of 10 hearts with damage, P < 0.05 vs. Ang II/salt) and adrenalectomy (2 of 10 hearts with damage, P < 0.05 vs. Ang II/salt). Our data indicate that aldo plays a major role in Ang II-induced vascular inflammation in the heart and implicate COX-2 and osteopontin as potential mediators of the damage.
我们在血管紧张素(Ang)II诱导的高血压模型中研究了醛固酮(aldo)在心肌损伤中的作用。给Wistar大鼠饮用1%氯化钠(盐)溶液,并随机分为以下几组(n = 10;治疗,21天):1)溶剂对照(VEH);2)输注Ang II(25 ng/分钟,皮下注射);3)输注Ang II加选择性醛固酮阻断剂依普利酮(epl,100 mg/kg·天,口服);4)在肾上腺切除(ADX)大鼠中输注Ang II;5)在接受aldo治疗(20 μg/kg·天,皮下注射)的ADX大鼠中输注Ang II。ADX大鼠还接受地塞米松(12 μg/kg·天,皮下注射)。除VEH组外,所有治疗组的收缩压均随时间升高(VEH,136±6;Ang II/NaCl,203±12;Ang II/NaCl/epl,196±10;Ang II/NaCl/ADX,181±7;Ang II/NaCl/ADX/aldo,236±8 mmHg)。尽管高血压水平相似,但epl和ADX减轻了Ang II诱导的心脏重量/体重增加。心脏组织学检查显示,Ang II/盐组(10只心脏中有7只受损,与VEH相比P < 0.05)和Ang II/盐/ADX/aldo组(10只心脏均受损,P < 0.05)存在心肌和血管损伤。损伤包括动脉纤维蛋白样坏死、血管周围炎症(主要是巨噬细胞)和局灶性梗死。血管病变与冠状动脉中膜炎症介质环氧合酶2(COX-2)和骨桥蛋白的表达有关。epl治疗(10只心脏中有1只受损,与Ang II/盐相比P < 0.05)和肾上腺切除术(10只心脏中有2只受损,与Ang II/盐相比P < 0.05)显著减轻了心肌损伤、COX-2和骨桥蛋白的表达。我们的数据表明,aldo在Ang II诱导的心脏血管炎症中起主要作用,并提示COX-2和骨桥蛋白是损伤的潜在介质。